Biomoda’s President Calls for Widespread Screening After Study Concludes Second-Hand Smoke Doubles Risk of Lung Cancer

Albuquerque, NM February 6, 2007 – The conclusions of a new study that second-hand smoke doubles the risk of lung cancer offers greater evidence of the need for widespread use of early lung cancer screening, said John Cousins, President of Biomoda, Inc. (“BMOD”) of Albuquerque, NM, maker of early lung cancer detection testing and other cancer diagnostic technology.

“Most everyone is exposed to second-hand smoke at one time or another and that exposure places most everyone at greater risk for lung cancer. Screening should be available not only for smokers, but the general public,” said Cousins in response to a study to be published in the March issue of American Journal of Public Health that reanalyzed 22 separate existing studies to prove that passive smoking significantly raises the risk of developing lung cancer. (http://www.ajph.org/cgi/content/abstract/AJPH.2004.061275v1)

Researchers will publish their findings next month in AJPH including a finding that even light levels of exposure to smoke raise the risk of lung cancer by 24 percent. People who are highly exposed to smoke in their workplace are twice as likely to contract lung cancer as a result, according to the study.

“Biomoda’s technology provides early detection of lung cancer using a non-invasive method that non-smokers, and others who don’t think they are at risk, may find easier to use,” said Cousins. “It’s a simple test that can be very useful on large scale for the smoker and non-smoker alike.”

Biomoda’s technology is based on a patented porphyrin application that preferentially binds to cancerous or aberrant cells extracted from lung sputum samples. Cancerous cells glow red under fluorescent light to allow detection under a microscope. The patented technology, a non-invasive cytology based assay, is designed for cancer screening at an early stage of large populations at a reasonable cost.

Lung cancer is the leading cause of cancer mortality in the United States, with 160,390 deaths expected in 2007. Rates of lung cancer in women are increasing, according to the report. The expected 5-year survival rate for all patients combined in whom lung cancer is diagnosed is 15 percent and by contrast, the 5-year survival rate for cases detected when the disease is still localized is 50 percent. At the present time, only 16 percent of lung cancer cases are diagnosed at this early stage.

“Safe Harbor” Statement: This press release contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations and are subject to uncertainty and changes in circumstances. Actual results may vary materially from expectations contained herein. Biomoda is under no obligation to (and expressly disclaims any such obligation) to update or alter its forward-looking statements, whether as a result of new information, future events or otherwise